CAJ | 학술논문

目的：观察DC－CIK联合化疗治疗中晚期胃癌的临床疗效以及安全性。方法将52例中晚期胃癌患者随机分为治疗组和对照组，对照组采用吉西他滨和奥沙利铂治疗，治疗组采用吉西他滨和奥沙利铂联合DC－CIK治疗，观察2组近期疗效、生活质量、1年生存率以及不良反应发生情况。结果治疗组客观缓解率为54％，疾病控制率为81％；对照组客观缓解率为46％，疾病控制率为58％。2组客观缓解率比较差异无统计学意义，而疾病控制率比较差异有统计学意义（ P ＜0．05）。治疗后，治疗组 KPS 评分显著高于对照组（ P ＜0．05）。患者免疫力提高，而对照组免疫力进一步降低，2组治疗后比较差异有统计学意义（ P＜0．05）。1年生存率2组比较差异无统计学意义，但是治疗组有延长的趋势。2组不良反应均为血液学毒性和消化道反应，但是治疗组不良反应比对照组明显减轻（ P＜0．05）。结论 DC－CIK联合化疗治疗中晚期胃癌的临床疗效优于单纯常规化疗，而且可以提高疾病控制率和患者生活质量，减轻不良反应，值得推广应用。
목적：관찰DC－CIK연합화료치료중만기위암적림상료효이급안전성。방법장52례중만기위암환자수궤분위치료조화대조조，대조조채용길서타빈화오사리박치료，치료조채용길서타빈화오사리박연합DC－CIK치료，관찰2조근기료효、생활질량、1년생존솔이급불량반응발생정황。결과치료조객관완해솔위54％，질병공제솔위81％；대조조객관완해솔위46％，질병공제솔위58％。2조객관완해솔비교차이무통계학의의，이질병공제솔비교차이유통계학의의（ P ＜0．05）。치료후，치료조 KPS 평분현저고우대조조（ P ＜0．05）。환자면역력제고，이대조조면역력진일보강저，2조치료후비교차이유통계학의의（ P＜0．05）。1년생존솔2조비교차이무통계학의의，단시치료조유연장적추세。2조불량반응균위혈액학독성화소화도반응，단시치료조불량반응비대조조명현감경（ P＜0．05）。결론 DC－CIK연합화료치료중만기위암적림상료효우우단순상규화료，이차가이제고질병공제솔화환자생활질량，감경불량반응，치득추엄응용。
Objective It is to observe the clinical effect and safety of Dendritic cell-Cytokine induced killers ( DC-CIK) combined with chemotherapy in the treatment of advanced gastric cancer.Methods 56 patients with advanced gastric cancer were randomly divided into two groups.The patients were treated by chemotherapy in gemcitabine combined with oxali-platin in the control group, and were treated by routine chemotherapy combining with DC-CIK in the treatment group.After treatment, the therapeutic effect, life quality, 1-year survival and toxicities of the two groups were observed.Results The re-mission rate ( RR) and disease control rate ( DCR) were 54%and 81%in treatment and 46%and 58%in control group re-spectively.There was no significant difference in RR (P>0.05) but was significant difference in DCR between both groups (P>0.05).after treatment, the KPS score was 85 ±17 of treatment group and 75 ±10 of control group respectively, there was significant difference between the two groups (P<0.05).The immunity was improved in the treatment group and de-clined in the control group obviously;there was significant difference in the immunity between the two groups.Compare with control group, the 1-year survival of treatment group was not remarkable but its survival time was more than control group. The main toxicities were hematological toxicities and digestive tract reactions in two group, but the treatment group was lighter than control group (P<0.05).Conclusion DC-CIK combined with chemotherapy has significant clinical effect on advanced gastric cancer and does not have obvious toxic and side effect.Moreover it can improve the RR, survival and quality.So it is worth popularizing and applying on clinic.